Scientific article
OA Policy
English

Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapy

Published in

BMJ oncology, vol. 3, no. 1, e000328

Publication date

2024

First online date

2024-04-08

Abstract

Objective: Immune checkpoint inhibitors (ICI) that block the programmed cell death 1 (PD-1) pathway have shown promise with limited benefit. We and others have shown in small patient cohorts that an early proliferative CD8 T-cell response in the blood may be predictive of clinical response. However, these studies lack detailed analyses and comparisons between monotherapy and combination therapies.

Methods and analysis: We analysed longitudinal blood samples from 103 patients with cancer who received αPD-1 monotherapy or combined with anti-cytotoxic T lymphocyte-associated protein 4 (αCTLA-4) or chemotherapy. Transcriptional analysis of CD8 T cells after the first treatment cycle with effector cells generated following yellow fever virus (YFV-17D) vaccine-induced infection was also compared.

Results: An early proliferative (Ki-67+ ) CD8 T-cell response was observed after cycle 1 in 60 patients (58.3%). Patients with early-and-sustained proliferative responses (cycle 1 and beyond) had better clinical responses and survival than patients with an early-but-limited response (p=0.02). The proliferating cells had an effector-like phenotype. The transcriptional profiles of the effector-like CD8 T cells were similar irrespective of treatment type or clinical response but distinct from that of YFV-specific effector CD8 T cells.

Conclusions: Our data suggest that early proliferative CD8 T-cell response in the blood is predictive, and that an early-and-sustained proliferative response may further identify patients with prolonged survival. The ICI-induced effector-like CD8 T cells are transcriptionally distinct from highly functional YFV-specific cells, suggesting opportunities for improved T-cell effector function with combination therapies for better clinical outcome.

Keywords

  • Biomarkers
  • Immunotherapy
  • T-lymphocytes

Funding

  • NIH/NCI [P30CA138292]
  • National Cancer Institute of the National Institutes of Health [P50CA217691]
  • National Center for Georgia Clinical & Translational Science Alliance of the National Institutes of Health [UL1TR002378]

Citation (ISO format)

OBENG, Rebecca C et al. Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapy. In: BMJ oncology, 2024, vol. 3, n° 1, p. e000328. doi: 10.1136/bmjonc-2024-000328

Main files (1)

Article (Published version)

Identifiers

Additional URL for this publication

https://bmjoncology.bmj.com/content/3/1/e000328

Journal ISSN

2752-7948
26views
60downloads

Technical informations

Creation

14/10/2025 07:38:36

First validation

26/11/2025 07:30:56

Update

26/11/2025 07:30:56

Status update

26/11/2025 07:30:56

Last indexation

02/11/2026 16:33:18
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated